Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00068211 | Study of ILX651 in Patients With Inoperable Locally Advanced or Metastatic Melanoma | PHASE2 | COMPLETED | - | — | — | Aug 1, 2003 | Jan 1, 2006 | Mar 5, 2015 | 19 | United States |
| Name | Type | Description |
|---|---|---|
| ILX651 | DRUG | - |
Inclusion Criteria: * Histologically or cytologically confirmed inoperable locally advanced or metastatic malignant melanoma. * Measurable disease. Measurable lesions should be outside the field of radiation. Where measurable lesions are within a previously irradiated field, there must be objective...